Yale Entrepreneurs-in-Residence

Entrepreneurs-in-Residence (EIRs) have deep operational experience and have gone through the process of turning new technologies to new businesses. These experts act as an early “sounding board” for Yale innovators contemplating a new startup. In a logical, stepwise fashion, EIRs help frame both the risks and the benefits of starting a new company, asking relevant questions about everything from the science, to the business, to the market and helping faculty chart a successful path forward. Each EIR has decades of practical private-sector experience in building their own companies and valuable connections with industry and investor communities. In addition to our EIRs, our Investor Advisors provide their professional investment experience, coupled with their technology and life science expertise, to provide astute insight into the competetive space our ventures wish to enter.


 

Marc Appel, J.D., M.B.A. 
 

Chief Executive Officer
Stealth Biotech Startup

Email: marc.s.appel@gmail.com

 

Industries and Specialities

Biotech, Healthcare

Marc Appel is an investor in the healthcare and biotech spaces. He helped to build the structured healthcare and royalty investing strategy at Marathon Asset Management, where he was instrumental on a range of large biotech deals. Prior to that, he invested across the capital structure in public market healthcare opportunities. Investments included companies in the specialty pharma, hospital, outpatient services, drug distribution, and biotech sectors. He also has extensive experience in work-out situations, where he restructured companies across a number of different industries.

Marc additionally serves as a financial and legal advisor to physician practices in areas such as business process optimization, billing best practices, and deal negotiation.

He has previously held roles at Highbridge Principal Strategies, Eaton Vance, and Kirkland & Ellis. He began his career as an analyst at McKinsey & Co. serving a mix of financial services and healthcare clients.

Marc received his B.A. from Yale University, his J.D. from Harvard Law School, and his M.B.A. from Harvard Business School. He is an active member of the NY bar.

Marc speaks on panels at a range of conferences in the healthcare space including CBI Trade Channel Strategies, Pharmacy Benefit Management Institute, and BIO CEO. He serves as an entrepreneur-in-residence to the Blavatnik program at Yale, a mentor to the Weill-Cornell eLab, and an adviser to Robertson Fund at Rockefeller University. He has also written a Harvard Business School case study on Imprimis Pharmaceuticals and has lectured at Harvard Business School, Harvard Law School, and Stern School of Business at NYU.  

Daniel Brill, M.B.A. 
 

Senior Advisor
H.S. Grace and Co.

Email: danielbrill@me.com

 

Industries and Specialities

Financial Services, Consulting

Dan has over forty years of wide ranging corporate experience in running businesses in the U.S. and Europe serving clients across a broad array of industries around the world for Citibank. Roles included, Global Head of Leverage Finance, Global Head of Strategic Initiatives, and Global Chief Risk Officer of Trade Finance and Cash, among others. Semi-retired since 2012, Dan currently serves as Senior Advisor of H.S. Grace and Co. to help lawyers win large cases involving complex business issues. As a volunteer at SCORE and the City of New Haven Business Academy, he helps local entrepreneurs start or grow their businesses. In the not-for-profit sectors, he serves as board chair of SARAH, Inc. (helps people with special needs) and as board member and treasurer of Madison Lyric Stage. Finally, Dan tutors formerly incarcerated people and “at risk” youth for EMERGE to help them earn high school degrees.

Richard Brodsky, M.S.
 

Head of Rare Disease Commercial Strategy
Augur Health

Email: brodsr@gmail.com

 

Industries and Specialities

Consulting, Marketing, Financial Services

Richard currently serves as the Head of Rare Disease Commercial Strategy for Augur Health. Recently, he has completed the successful neurology development, and launch of a rare disease drug for Myasthenia Gravis. Prior to Augur, he worked for more than 20 years in the pharmaceutical industry serving roles as Director of New Business for Pfizer and Global Neurology Marketing Leader for Alexion Pharmaceuticals. Richard has extensive experience as a senior business leader, specifically in new product development and launch, marketing, business operations, business development, and finance. 

Ashok Chetty, Ph.D. 
 

Global Innovation Leader
Dupont

Email: ashokchetty@hotmail.com

 

Industries and Specialities

Consulting, IT, High Technology Materials & Processing

Ashok is the Global Innovation Leader at DuPont. He has been involved in leading and managing innovation at DuPont for over 20 years. He leverages his own experience in launching new products and new businesses to coach a large number of global teams to commercialize their innovative ideas across a variety of domains. He has a passion for learning and trying new approaches to solve long standing problems. As a result, his career has included new business development, new product development, marketing, business strategy, and technology leadership roles in businesses serving a variety of industries such as automotive, construction, worker safety, environmental protection, specialty chemicals, and packaging.

Ken Coleman, M.B.A.
 

Director of EVP Operations
C8 Sciences

Email: kencoleman184@gmail.com

Industries and Specialities

Consulting, Marketing

Ken Coleman co-founded CS Sciences™ in early 2011 following a career as a senior operating executive and then as an entrepreneur and strategy advisor to businesses in several industries.During the past 15-years, Ken has advised the CEOs and Boards of entrepreneurial businesses ranging from startup ventures to mature turnarounds on strategies for development and growth, with particular focus on product/market strategies, operating plans and financial planning. These companies employed a wide range of technologies in a various industries including medical devices, communications electronics, sports products, internet software and services and clean-tech chemistries. In some instances, he co-founded and/or assumed an interim operating role as CEO or COO. He has also been an Operating Partner with Endeavor Capital Management, a private equity firm in Westport, CT. 

Arthur DeCillis, M.D., M.S.
 

President
DeCillis Consulting, LLC

Email: arthur.decillis@comcast.net

Industries and Specialities

Biotech, Drug Development, Oncology

Arthur DeCillis currently serves as the president of DeCillis Consulting LLC, a company that provides oncology strategic, medical, and operational consulting services to the pharmaceutical and biotechnology industries. Prior to forming his own consulting practice, Arthur was the Chief Medical Officer for Eleven Biotherapeutics (now known as Sesen Bio Inc.), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies. Previously, Arthur was the Vice President of Clinical Research and then Vice President of Medical Affairs at Exelixis, Inc., an oncology-focused biotechnology company. Prior to this, Arthur served as Executive director of Phase 2 and Phase 3 Oncology Development at Novartis. He also served as the Group Director of Bristol-Myers Squibb. Arthur has been involved in the development of several commercial drug including Sprycel (dasatinib), Afinitor (everolimus), Farydak (panobinostat), and Cabometyx (cabozantinib).

John E. Derrick
 

Chief Executive Officer
Skywriter Systems, Inc.

Email: jederrick@icloud.com

Industries and Specialities

Consulting, High Technology Materials & Processing

Key strengths: Identify and communicate the core value of a nascent technology or product offering, create a strategy and operational plan to deliver that value, and lastly, align and lead the existing team(s) to excel in the delivery of that value.

Key tasks: Strategic plan, business model, fund-raising, strategic partnerships, growth and scale.

Key technologies: Processors of all types, Semiconductors, Materials, AI / Machine Learning, Networking & Security. Companies acquired by: VMWare, Kemet, ARM, NetApp, Qualcomm, Intel, Parthus Technologies

Incubators & Universities: Advised and assisted companies formed and spun out of Yale, University of Texas, Stanford, Iowa State, University of Penn, many others.

John Dexheimer, M.B.A.
 

President
LightWave Advisors

Email: john.dexheimer@yale.edu

Industries and Specialities

Consulting, Software/SaaS, Financial Services

John Dexheimer is President of LightWave Advisors, Inc. where he assists IP rich start-ups and established firms in new ventures, expanding partnerships and M&A for firms in software, communications, electronics, photonics and materials. He has assisted in capital formation, operational and partnering execution resulting in monetization of over 100 firms, with several valued at over $1 billion.

John has had several part-time operating roles in startups and mature technology firms with revenue of up to $400 million, in addition to serving on several Boards of public and private firms. John has a deep history with venture capital investing as a co-investor and advisor on portfolio firms of many of the well know, active investors in technology sectors.  He has helped found start-ups and has a record of initiating and structuring successful private investments for affiliated equity funds – including investments resulting in over a dozen IPOs. He has been a GP since 2003 of First Analysis Private Equity Fund IV, and previously was a partner in several angel and VC funds. He led the IPO of several firms and subsequently managed the equity research of an investment bank, covering technology and healthcare sectors.

John is an Advisory Member to the NSF Institute of Mathematics and its Applications, and is on the corporate and start-up advisory boards of several trade groups focused on photonics and imaging technologies. He holds a B.S. from the University of Minnesota, College of Science and Engineering where he is on the Dean’s Advisory Board, and received an MBA from Harvard University.

Brian Dixon, Ph.D.
 

Venture Partner
Elm Street Ventures

Email: brian@elmvc.com
 

Industries and Specialities

Biotech, Infectious Disease, Oncology

Brian has been active in the New Haven area biotech community since joining Bayer in 1993. While a scientist there, he directed drug discovery efforts in both the Osteoporosis and Oncology therapeutic areas, where his research groups advanced a number of drug candidates into development. As a Bayer HealthCare Vice President he led a multi-disciplinary organization that delivered state-of-the-art expertise in oncology biomarker discovery, new lead discovery, research drug formulation, pharmacokinetics and drug metabolism to the company’s global R&D business. In addition, he held leadership roles in R&D licensing initiatives, strategic alliances and cross divisional collaborations in translational medicine. After Bayer, Dr. Dixon joined BioRelix, Inc. as President & CEO where he and his team built an infectious disease focused biotechnology company based on academic technology licensed from Yale University. More recently Brian has been advising founders, investors and companies in the biotechnology space.

Dr. Dixon was an undergraduate at the University of Michigan, received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and completed post-doctoral training at Harvard University in the labs of Nobel Laureate Elias J. Corey.

Konstantine Drakonakis, M.E.M., P.E.
 

Director/Venture Partner
LaunchCapital

Email: konstatine@launchcapital.com

Industries and Specialities

Medical Devices, Financial Services, High Technology & Processing

Konstantine is an experienced early stage investor and operator focused on developing proprietary IMPACT technology companies. As an “Entrepreneurial Engineer,” he gravitates to technology companies within the software, med-tech and green-tech markets. He has led over 40 investments for LaunchCapital and the Pritzker Vlock Family Office (PVFO) to date and serves as a strategic advisor for many of his portfolio companies. He represents LaunchCapital and PVFO as a board member on the following portfolio companies: Amastan Technologies (where he was the founding Chairman and CSO), EpiEP, Biorez, TearSolutions, and Affinimark Technologies. 

Konstantine is actively involved in the incubation/inception stage of the entrepreneurial ecosystem and serves as an advisor to BioCT’s Bioscience Clubhouse, the Entrepreneurship Foundation, the Donaghue Foundation, and the District Venture & Innovation Center. He is also a Mentor in Residence at the TSAI Center for Innovative Thinking at Yale and a member of the Yale Whitney Avenue Innovation Fund Investment Committee. 

Mr. Drakonakis was the Manager of New Technology Investments and Infrastructure Development at Connecticut Innovations. He holds a Masters in Environmental Management from Yale University and a Civil and Environmental Engineering degree from the University of Vermont. He is a board certified Professional Engineer and is a member of the National Civil Engineering Honors Society.

Seth Feuerstein, M.D., J.D.
 

Executive Director and Founder
Center for Digital Health and Innovation, Yale University School of Medicine

Email: seth.feuerstein@yale.edu

Industries and Specialities

Therapeutics, Medical Devices

Dr. Feuerstein has expertise across multiple areas of medicine including Suicide Prevention, Technology and Suicide, Telehealth, Social Media and Mental Health, Digital Medicine, Suicide, Digital Health, Digital Therapeutics, Healthcare Innovation, Emerging Medical Technologies, forensic psychiatry, technology transfer, technology investment, intellectual property and the intersection of technology, law and medicine. He is a founding board member of the Center for Biomedical and Interventional Technology at Yale and Executive Director of the Center for Digital Health, Innovation and Excellence. He teaches at the medical school and is the faculty advisor for Innovation in Healthcare at the Yale School of Medicine. He works across multiple sectors in healthcare including health insurance, healthcare startups, healthcare investing, clinical care delivery innovation and early stage emerging medical technologies. 

Colin Foster, M.B.A.
 

Chief Executive Officer
iSci Management, LLC

Email: fostercjf@gmail.com

Industries and Specialities

Therapeutics, Diagnostics, Medical Devices

Colin has thirty years of experience as a public and private life science company Chairman, Executive Chairman, Board Member, CEO, and entrepreneur with leadership experience across the R&D-commercial continuum in therapeutics, diagnostics, and medical devices.  He has led multi-billion-dollar, midsized, small, and start-up life science companies in the USA, Canada, United Kingdom/Ireland, and Israel.  He began his career in pharmaceutical marketing & sales ultimately becoming President & CEO of Bayer Pharmaceuticals North America, following which he co-founded and was CEO of Optherion Inc, a venture-backed biotechnology company leveraging Yale technology.  Subsequently, he was Executive Chair of Ivenix Inc, a venture-backed medical device company, President & CEO of Bioblast Pharma, a public biotechnology company, and founder of iSci Management, a strategic advisory firm.  Colin has a B.Sc. in Zoology and Microbiology from the University of Toronto, an M.B.A. from the Ivy School of Business, Western University, and his Canadian Securities Certificate.

Susan Froshauer, Ph.D.
 

Vice President
CURE Collaborations

Email: susan.froshauer@yale.edu

Industries and Specialities

Drug Development, Therapeutics, Infectious Disease

Dr. Froshauer has joined Yale Office of Cooperative Research as an Entrepreneur in Residence, returning to one of her passions, connecting entrepreneurs to know-how, funding and approaches that ultimately may improve our quality of life. Susan also is a leader of the CURE Commons accelerator programs, especially assisting with a Thames River community entrepreneur outreach as part of a CTNext Innovation Places funded program, Ignite. She recently stepped-down from her role as President and CEO of CURE in order to better focus her time as a tech/biotech start-up executive. She is an experienced scientist, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector.  Susan serves on the Boards of Carogen, LambdaVision, Bioxiness, Thames River Innovation Partners and is a business advisor to Alva Health and HLK Pharma. In addition to CURE and the Yale Entrepreneurial Institute, Susan has been involved with the CTNext funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role, Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars. Until 2010, Susan served for 11 years as the founding President and CEO of Rib-X Pharmaceuticals (now Melinta), which she co-founded in New Haven in 2000. Under her leadership, Rib-X raised more than $160 million in private equity, bridge financing and government grants and built an emerging pipeline of antibiotics to treat serious hospital infections. Melinta is launching its first product as it goes public in the next few weeks. Prior to Rib-X, Susan served as a member of Pfizer’s Strategic Alliance Groups where she was part of a team involved in the creation of a $200 million investment portfolio that at the time transformed the Pfizer global research and development strategy. She received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B.A. from Connecticut College. She performed post-doctoral research at Yale Medical School in the Department of Cell Biology as a Jane Coffin Child’s Fellow.

Matthew Gordon, M.S., M.B.A.
 

Clinical Manager for Advanced Practice Providers
Yale New Haven Hospital

Email: matthew.gordon@yale.edu

Industries and Specialities

Healthcare, Cardiovascular

Matthew Gordon is a Clinical Manager for Advanced Practice Providers at the Heart and Vascular Center of Yale New Haven Hospital. Prior to this role Matthew served in the United States Army as a Combat Medic for the 82nd Airborne Division. He then worked as the Lead Cardiac Physician Assistant and Clinical Manager for Cardiac Surgery at Johns Hopkins Hospital 

Gene Griffin, D.V.M., M.S.
 

Consultant
Biologicals Development

Email: griffinvet1@gmail.com

Industries and Specialities

Drug Development, Immunology

Gene Griffin is an immunologist with 28 years of drug development experience in pharmaceutical and biotechnology companies including a Danish start-up company.

Formerly, for eight years, he was a Senior Director at Alexion Pharmaceuticals in R&D and Business Development. In this capacity, Gene was instrumental in the expansion of Soliris® (C5 antibody) into additional complement-mediated rare diseases and is a co-inventor on several of the patents. He contributed to the company’s diversification into enzyme replacement therapies (Strensiq® and Kanuma®) and exploration of RNA technologies and gene therapy as therapeutics in rare diseases. Additionally, he fostered and managed business partnerships with companies and academic institutions, including Yale University.

Previously, he worked in multiple disease indications with small molecule and protein therapeutics at Biogen, Bristol-Myers Squibb (BMS), Sandoz, and Parke-Davis in various discovery and development responsibilities. Also, at the Convatec Division of BMS, he helped developed medical devices and is co-inventor for medical use of one device.

Gene earned his Doctor of Veterinary Medicine degree at Tuskegee University and is a member of Phi Zeta Honor Society. He earned his Master and Bachelor of Science degrees from the University of Connecticut. He did his Postdoctoral research in Transplantation-Related Vascular Immunology at the Milton S. Hershey Medical Center, Pennsylvania State University.

Rosemary Harry, M.S.
 

President
Device Foundations

Email: rharry@devicefoundations.com

Industries and Specialities

Medical Devices, Consulting, Orthopedic

Rosemary Harry has more than 25 years experience in the medical device industry, including senior management positions responsible for quality assurance, regulatory affairs and clinical studies. The majority of Ms. Harry’s career has been focused on early stage companies where she was also a key team member in corporate strategic planning, business plan development, and program management. As President of Device Foundations, Ms. Harry serves as a consultant to start-up companies, as well as academic researchers in support of NIH and other funding, most recently with programs in orthopedics, dermatology, aesthetics, diagnostic imaging, cardiovascular, and neurology. 

Brian E Harvey, M.D., Ph.D.
 

Principal Consultant
Brian E Harvey, LLC

Email: bharvey@globalliver.org

Industries and Specialities

Biotech, Medical Devices, Gastroenterology

Brian E. Harvey, MD, PhD is a physician and biochemist with academic research, clinical practice, U.S. FDA regulatory, bio-pharmaceutical industry and non-profit experience.  He currently is the Executive Vice President, Science and Regulatory at the non-profit Global Liver Institute in Washington, DC.  Prior to his current activities, Dr. Harvey held positions as Vice President of U.S. Regulatory Strategy at Pfizer and Vice President of U.S. Regulatory Policy at Sanofi-Aventis, including during the period of the Genzyme merger.

Dr. Harvey also held several senior roles at FDA, serving in the medical device (CDRH), biologic (CBER) and drug (CDER) Center from 1995 to 2007.  As Director of CDER Division of Gastroenterology Products Office of New Drugs (OND), he headed the regulatory review teams for NDA and BLA submissions and chaired FDA meetings with regulated industry on a regular basis.  As Director, he created the Inborn Errors of Metabolism Team within the GI division to focus on rare disease product approvals.  Prior to this, he served as Deputy Director for the Office of Drug Evaluation 5 (CDER) and CBER Associate Director for Policy, Office of Therapeutics Research and Review (OTRR). 

Brian graduated with honors from Middlebury College in Vermont.  After college, he received his PhD in biochemistry, followed by his MD at the University of Connecticut.  In his last year of medical school, he began post-doctoral research on colorectal cancer and the role of sialic acid in site-specific metastasis at Harvard University.  He completed his internship and residency in internal medicine at Harvard’s Beth Israel Hospital, which included clinical rotations at Dana-Farber Cancer Institute, West Roxbury Veterans Hospital, clinical research at Brigham and Women’s Hospital and the Harvard School of Public Health.  His bench research activities at Harvard resulted in several publications in peer reviewed journals.  This was followed by a three year gastroenterology fellowship at Johns Hopkins Hospital, Baltimore, MD.

Jessica Hwang
 

Strategic Consultant
Jessica Hwang

Email: jessicahwang@gmail.com

Industries and Specialities

Marketing, Medical Devices

Jessica is a global healthcare consultant with over 10 years in pharmaceutical and medical devices, at companies including Johnson & Johnson, Pfizer and MicroVention-Terumo Medical, with 8+ years in the neurovascular space. She is experienced in global marketing, business strategy and intelligence, new ventures and market access/regulatory affairs. She helped secure global funding, launch portfolios globally, expand the geographical reach of international markets, identify acquisitions and deliver market analyses and competitive landscape assessments. 
 
Her international experience includes 6+ years of sales & marketing in Japan, Singapore, Hong Kong, Australia, New Zealand and Emerging Markets, including China & Asia Pacific and Latin America.  She led J&J’s Micrus/Codman (neuro) portfolio launch in China.

 

Jessica holds a B.S. in Business Administration from Cornell University and is fluent in Mandarin with training at National Taiwan Normal University’s Mandarin Training Center.    

Tom Jasinski
 

Principal
IntraVentures, LLP

Email: thomas.jasinski@yale.edu

Industries and Specialities

Marketing, Software, Consulting

A Yale College grad (JE ’78), Tom’s background includes an unusually wide range of US and international corporate and entrepreneurial experiences. His corporate work includes pan-European marketing responsibility for a portfolio of flagship Mars brands (Mars, Snickers and Twix), as well as several major ad agencies with clients like P&G, Duracell, Exxon, Seagram’s, Quaker, Kraft, Alka-Seltzer, Nintendo and Radio City Music Hall. Tom has specific expertise in FMCG new product development, brand management, international marketing, food and wine, software, retail, media, creative services management and entertainment. His entrepreneurial experience includes a Sand Hill Road/VC-backed early stage software startup based in SF and Austin, a retail JV development with a public company and a bootstrap/garage-based startup (literally) with a very successful software developer.

Kristin King, M.B.A.
 

Vice President
Corporate Development & Strategy at Defibtech, LLC

Email: kristinkingmba@gmail.com

Industries and Specialities

Medical Devices, Cardiovascular, Infectious Diseases

Kristin is an accomplished MedTech executive, serial intrapreneur, investor and strategic advisor to startups developing biotech solutions.  With a distinguished career addressing commercial strategy over 20 years spanning technical, marketing, and business development disciplines, she offers multidiscipline expertise and repeated track record for high impact Medical Device development transforming technologies from early concept to successful global divisions at leading Medical Device companies and startups.

Kristin is recognized for her strategic development, business acumen, and her ability to build and lead talented teams to commercialize products that change patients’ lives.  Starting her career designing stents, a patent inventor for Johnson & Johnson’s drug eluting stent and progressing through marketing and global commercial leadership roles she has contributed to some of the world’s most meaningful programs at top healthcare firms including Ansell Healthcare, Becton Dickinson, Johnson & Johnson Cordis, Abbott Vascular, and Pfizer.  Her category expertise includes advanced wound care, infection prevention, diabetes care, interventional cardiology/ radiology, and other surgical specialties in hospital, alternate site and consumer retail segments.   

In 2017, after founding Ansell Healthcare’s advanced therapeutic segment, Kristin focused her career on the Boston startup community progressing MIT spin off Rogers Sciences to clinical trials, FDA submission as well as proud member of Boston Harbor Angels.  Kristin holds a B.S. in bioengineering from Syracuse University, MBA in Finance & Marketing from NYU Stern.   Outside of the office she is an avid scuba diver and volunteer for environmental organizations Beneath the Sea and Boston Sea Rovers.

David Kolb, M.B.A.
 

Founding Partner
Raphael Capital Partners, LLC

Email: david@raphaelcapital.com

Industries and Specialities

Biotech, Consulting, Diagnostics

David is a life science entrepreneur and former investment banker. He has been in the biotech investment field for over two decades having founded four companies and having completed over 70 transactions valued at over $2.5 billion. His current interests include clinical supplements focused on kids, diagnostics for unmet medical needs, cancer metabolism and subcellular targeting. He is a Founding Partner of the life science incubator, Raphael Capital Partners LLC. While serving that role he has founded/created a portfolio of life science companies across the areas of diagnostics and therapeutics in the areas of wound care, CNS, cancer and cardio/metabolic. He is also a Founder and Chairman of the Board for Emunamedica LLC, a non-invasive wound diagnostics company, with the goal of providing wound care diagnostic support for clinicians, to generate better outcomes for patients, in a cost-effective manner for insurance companies and Medicare. 

Michael Kurman, M.D.
 

President
Michael Kurman Consulting

Email: mkurman@mkurmanconsulting.com

Industries and Specialities

Biotech, Drug Development, Consulting

Dr. Kurman currently serves as the President at Michael Kurman Consulting. He has spent over thirty years in the oncology drug development field. He is a board-certified medical oncologist who practiced community oncology in New Jersey where he participated as an investigator in oncology clinical trials sponsored by the Eastern Cooperative Oncology Group (ECOG) and the Memorial Adjunct Staff Oncology Group (MASOG). During his career in the pharmaceutical industry, he has held positions of progressive responsibility at large-pharma, emerging-pharma and CRO companies. 

Ron Lennox, D.Phil., M.B.A.
 

Chief Executive Officer
Monogram Orthopedics

Email: rlennox@aliaventures.com

Industries and Specialities

Biotech, Diagnostics

Ron has invested broadly in the life science sector with an emphasis on biotechnology and molecular diagnostics. He is currently CEO of Monogram Orthopaedics, Inc., a spin-out from Mount Sinai School of Medicine where he also serves as an EIR. Monogram, which is based in Brooklyn, is developing the next generation of orthopaedic implants and surgical tools. He has served on the boards of eighteen companies including General Surgical Innovations, Inc. (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson), Protometrix, Inc. (acquired by Invitrogen Corp.), and Applied Molecular Evolution Inc. (acquired by Eli Lilly). He was founding Chairman of Amicus Therapeutics (NASDAQ: FOLD, another Mount Sinai spin-out) and Chairman of Bikam Therapeutics where he managed its sale to Shire in 2014. He was founding CEO of two Yale start-ups, Protometrix, Inc. and CGI Pharmaceuticals, Inc (acquired by Gilead Sciences, Inc.). He was one of the three founding partners of CHL Medical Partners, and prior to that was a general partner at Hancock Venture Partners (now HarbourVest Partners) where he invested in sixteen healthcare companies, ten of which had successful IPOs. Ron graduated from the University of Glasgow with a B.Sc. in Molecular Biology, Oxford University where he received a D.Phil. in Cell Biology and the Wharton School of the University of Pennsylvania where he received his MBA.

Lawrence Lipsher, M.B.A.
 

Director
Metal Morphing Technologies, Inc.

Email: l.lipsher@snet.net

Industries and Specialities

Consulting

Lawrence Lipsher is managing partner of Martin Associates, L.L.C., a management and financial advisory firm providing strategic and financial consulting services to small and middle market private companies. Currently, he serves as Director of Metal Morphing Technologies, Inc., a company formed in 2011 to develop processes that will enable bulk metallic glasses to be incorporated in a range of innovative commercial applications. He has held strategic operating positions in manufacturing, has initiated and closed acquisitions, divestitures and financings and has been a principal in U.S. and international startups. 

James Locker, M.S., M.B.A.
 

Managing Principal
CenterPoint Partners

Email: N/A

Industries and Specialities

Consulting, Marketing

Jim Locker is the Managing Principal of CenterPoint Partners as well as being on the board of the Tread Corporation. He is a proven CEO, private equity operating partner, board member, and consultant (large global, private and PE-owned companies). He is experienced in mass market retail, industrial distribution and OEM channels effectively translating customer expectations into actionable plans. He has also served as a mentor for Arix, a software venture dedicated to determining internal pipe corrosion in refinery and petrochemical facilities, EZ Ice, an enterprise focused on developing a portable ice skating rink, and Isoplexis, a ventured focused on developing technology that will improve drug discovery process and results, as part of the Yale Entrepreneurial Institute. 

Alexandra Mack, Ph.D., M.A.
 

Principal Researcher and UX Lead
Ad Hoc, LLC

Email: alexandra.mack@yale.edu

Industries and Specialities

Consulting, Marketing, Software

Alex leads innovative problem solving and strategy development based on a deep understanding of the surrounding culture and activities. She has brought this combination of customer-centered design, innovation, market research, opportunity identification, business planning, and cultural change to projects across verticals, including health care, retail, software, and financial services. She was a Senior Fellow in Pitney Bowes’s Strategic Technology and Innovation Center, and prior to Pitney Bowes, she spent several years consulting in marketing, design, and strategic research. From 2011-2017 she served on the Executive Board of EPIC, an international organization whose membership drives the integration of human centered perspectives, methods, and theory into business practices. Since 2013 she has been a member of the ACM’s Distinguished Speaker Committee. Alex received her PhD in Anthropology from Arizona State University. She also holds an MA in from the University of York and an AB in Anthropology from Harvard University.

Bridget Martell, M.D., M.A.
 

Founder & Managing Director
BAM Consultants

Email: bridget.martell@yale.edu

Industries and Specialities

Drug Development, Immunology, Oncology

Dr. Martell has over 15 years of experience in the Pharmaceutical/Biotechnology industry as a Chief Medical Officer, and strategic/scientific advisor, working across all stages of clinical drug development including work on the successful approvals of Kadcyla® Elelyso ® and Intermezzo® and secondary indications for Pradaxa® and Sutent®. She has experience with large and small molecules, biosimilars, combined drug devices, and vaccines within oncology, immuno-Oncology, rheumatology, pain, orphan diseases, CNS, cardiovascular, and women’s health. She is currently Managing Director and founder of BAM Consultants, LLC, a clinical/scientific advisory firm and prior to this, was Senior Vice President of New Product Development and Chief Medical Officer of Juniper Pharmaceuticals, a public company with a focus on Women’s Health therapeutics. Dr. Martell’s previous work included leading medical affairs at Purdue Pharma and clinical development and medical affairs at Pfizer as the Biosimilars Medical Head. She also held senior clinical development roles at other business units within Pfizer’s biopharmaceutical businesses. She began her clinical investigation career at Yale with a Career Development Award and as a Faculty Auditor in the Robert Wood Johnson Clinical Scholar conducting the first therapeutic cocaine vaccine trial for adjunctive treatment for cocaine dependence. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Ryan McMillian
 

Managing Director and Founder
RM Consulting, LLC

Email: ryanmcmillianllc@gmail.com

Industries and Specialities

Financial Services, Therapeutics, Biotech

Ryan is an experienced finance executive focused in the life science industry. He is currently Managing Director and founder of RM Consulting LLC, a strategic advisory firm specializing in valuation modeling, capital allocation, and part time CFO services. Previous to this, Ryan was the Head of US Finance for Alexion Pharmaceuticals providing financial leadership, strategy, and planning to the region as well as lead the launch of 3 orphan drug launches and oversee US pricing strategy and reporting. Ryan joined Alexion as the Assistant Treasurer focused on building global cash operations, insurance management, and capital raising. Prior to joining Alexion, he spent several years in corporate finance and banking at GE Capital. 

Sean McNerney
 

Co-Founder
360 Life Sciences Advisors

Email: seanmcnerney1@gmail.com

Industries and Specialities

Consulting, Marketing, Medical Devices

Sean is an accomplished senior executive with over 25 years of medical device commercialization expertise. As an executive leader, Sean is driven by a passion for emerging, disruptive technologies and the opportunities to leverage product innovation to enter new markets while driving towards market leadership. As co-founder of 360 Life Sciences Advisors, he works with private equity and venture capital firms to improve performance in their portfolio companies and also assess new investment opportunities. Additionally, he engages with early stage companies to assist with their strategic and commercial growth plans. Prior to consulting, he was U.S. Country Manager, VP Sales & Marketing for Sorin Group (now LivaNova), a medical technology company specializing in cardiac devices for surgery. In this role, he held General Manager level, P&L accountability for the U.S. Perfusion and Heart Valve businesses. Prior to that, Sean served as U.S. Vice President of Sales & Marketing at Covidien (now Medtronic), where he held full P&L responsibility for three business units with combined $350M annual revenue. 

Sean Mehra
 

Chief Strategy Officer
HealthTap

Email: sean@mehra.fm

Industries and Specialities

Sortware/SaaS, IT, Healthcare

Sean is an entrepreneurial executive dedicated to leading exceptional teams to distribute inventions that enhance our quality of life, the survival of our species, and the health of our planet. He is focused on forming and operating early to growth stage, high tech ventures to achieve significant scale, commercial success and fulfillment of a meaningful mission. Sean is currently the Chief Strategy Officer at HealthTap, a digital health company dedicated to creating universal access to quality healthcare for millions worldwide. In the first 7 years of his tenure, he was Chief Product Officer and one of the founding members, helping to lead the organization from a seed-stage startup in private beta to a growth stage company with $85M in financing, eight-figures in annual consumer and enterprise revenue, and over 350 million consumers served. Prior to that, Sean was Founder & CEO of PayoutHub, a social game-monetization platform that was acquired, and the Founder & COO of GXStudios, a venture-backed, team-based casual games platform. Sean advises startups regularly through VC firms, Stanford’s Center for Entrepreneurial Studies, and the Yale Entrepreneurial Institute (now “TSAI City”), Yale University’s official incubator and fellowship program for entrepreneurs.

Sridhar Narayan, Ph.D., E.M.B.A. candidate
 

Head, Drug Discovery and Development
Satellos Bioscience

Email: sridhar.narayan@yale.edu

Industries and Specialities

Drug Development, Oncology, Immunology, Infectious Diseases

Sridhar Narayan is a scientist and entrepreneur who brings extensive experience from the life sciences industry. He’s currently the Head of Drug Discovery and Development at Satellos Bioscience, which he helped launch in 2018. In 2015, he was involved in starting Appili Therapeutics where he serves as Project Director and Member of the Scientific Advisory Board. Sridhar also consults with biotech and VC firms on new ventures, drug discovery & development, strategy, and business development. Previously, Sridhar held scientific leadership positions at Navitor Pharmaceuticals, AstraZeneca and Eisai, where he led projects from early discovery through IND and FIH studies. He has a track record of moving several compounds into clinical development and his expertise spans oncology, immunology/ inflammation, metabolic disorders, CNS and infectious diseases. Sridhar received his PhD from the University of Michigan and carried out postdoctoral research at the Scripps Research Institute. He’s in the Executive MBA program at the Yale School of Management.

Sarah Nia, Pharm. D.
 

New Products Marketing and Planning Lead
Regeneron Pharmaceuticals

Email: sarahnia19@gmail.com

Industries and Specialities

Marketing, Therapeutics, Oncology

Sarah Nia has over 15 years of biotechnology start-up and mature experience in medical, commercial, diagnostic roles in US and globally including healthcare, research, sale and marketing strategies, product launch planning and building cross-functional organizations from ground up in the United States, European Union and Latin America. She currently serves as the New Products Marketing and Planning Lead for Regeneron Pharmaceuticals. Previously, she held a position as the Head of Global Gene Therapy Sales and Genetic Diagnostic Strategy for Spark Therapeutics, as well as, Senior Director of Commercial Clinical Sciences and Global Diagnostic Strategy for Alexion Pharmaceuticals. While there she manage two field facing cross-functional teams in support of Soliris sales for PNH and aHus. 

Sophia Ononye, Ph.D., M.P.H., M.B.A.
 

Founder
The Sophia Consulting Firm

Email: sophia@sophiaconsultingfirm.com

Industries and Specialities

Consulting, Marketing, Therapeutics

Sophia Ononye is an integrated marketing and communications professional with a core in scientific strategy. She recently founded The Sophia Consulting Firm where she leverages her multidisciplinary education, broad therapeutic area experience and passion for amplifying scientific innovation to lead the provision of fully integrated communication services for clients in the biotechnology, pharmaceutical and medical device space. A Yale and UCONN alumna and former Pfizer Scientist, Sophia’s niche for fostering partnerships has resulted in a diverse range of experiences where she has supported emerging and established biopharmaceutical and medical device companies with market access, personalized marketing, launch preparedness, strategic alliance management, corporate strategy, scientific communications, corporate communications, public relations and investor relations. She is trained in hematology and oncology with demonstrated experience in epigenetics, targeted therapies, combination therapies, checkpoint inhibitors, CART cell therapies and other cancer immunotherapies. Sophia also has broad therapeutic experience in rare diseases, women’s health, pain management, and infectious diseases. 

Timothy A. Riley, Ph.D.
 

Chief Scientific Officer/Chief Business Officer
Rett Syndrome Research Trust

Email: timothy.riley@yale.edu

Industries and Specialities

Biotech, Therapeutics, Oncology

Emotionally intelligent, entrepreneurial Executive in the pharmaceutical and biotechnology industry with multiple drugs approved and approaching approval.  These products are projected to be multi-billion dollar products and have created over $1.5 billion in market capitalization.  Built and led successful teams in pharmaceutical research and development with over three decades of experience. Leadership positions include Executive position in business development for a top tier research medical school, decade long tenure as Executive Committee member of a publicly traded company, SVP of Global Research, and SVP of Quality. Directed internal and external international relationships. Therapeutic areas include Rare Diseases, Hemophilia, Pain, Oncology, Antivirals.  Areas of technical expertise: large molecules including oligonucleotides, peptides and proteins; small molecules including heterocycles, nucleosides, carbohydrates as well as retooling or rescue of existing drugs with lipid and PEG technologies. Co-founded a target validation company, linking genes to their importance in disease.  Proven ability to influence investors to make financial commitments to new entities.  Successfully interfaced with finance, biology, chemistry, clinical, regulatory, QA, manufacturing, and business development functions.

Barry Schweitzer, Ph.D.
 

Venture Partner
Elm Street Venture

Email: barry.i.schweitzer@dartmouth.edu

Industries and Specialities

Biotech, Consulting, Oncology

Barry is a Venture Partner at Elm Street Ventures with 20 years of years of experience in executive management and leadership positions. Most recently, Barry served as Chief Executive Officer of Glygenix Therapeutics, Inc., a Connecticut-based gene therapy company developing treatments for a group of orphan diseases in children. He was also Principal of BLS Partners LLC, a management consulting firm. Before starting BLS Partners in 2014, Barry was an R&D and business leader in one of the world’s largest life sciences companies, Life Technologies Inc. He has also been a serial entrepreneur, helping to start up two biotechnology companies that were spun out of Yale University, including Molecular Staging Inc., which he joined in 1998 as Director of R&D, and then Protometrix, Inc., where he was the Senior Director of Technology when it was acquired by Invitrogen Corporation in 2004. Prior to entering the biotechnology sector, Barry was an Assistant Professor in the Department of Chemistry at the University of Central Florida. Before moving to Florida, he was a Leukemia Society Special Fellow in the Department of Pediatrics at Yale University School of Medicine, and a post-doctoral fellow at the Memorial Sloan-Kettering Cancer Institute. Barry received his Bachelor’s degree from Dartmouth College and his Ph.D. in Pharmacology from Yale University.

Sapan Shah, Ph.D.
 

Founder and Chief Executive Officer
Novatherx

Email: sshah@novatherx.com

Industries and Specialities

Consulting, Biotech

Dr. Shah is Founder and CEO of Novatherx, a life science company providing expertise, leadership and investment support to biotech and pharmaceutical companies advancing innovative therapeutics that address areas of critical unmet medical need.

Over the past 20 years, Dr. Shah has worked to advance products and lead companies in the life sciences area.  He was previously President and CEO of ARMGO Pharma, a biotechnology company launched from Columbia University developing novel small-molecule therapeutics to treat debilitating cardiac and rare muscle diseases.  Dr. Shah also served as President and CEO of Shionogi, Inc., where he expanded the US pharmaceutical business of Shionogi & Co., Ltd., growing from its inception as a small clinical development subsidiary to ultimately a fully integrated commercial entity with $400M in sales and over 400 employees.  At Shionogi he also led efforts to negotiate, structure, launch, and operate a highly successful joint venture between Shionogi and GSK/ ViiV, resulting in the discovery, development and commercialization of a novel HIV integrase inhibitor.  In addition, Dr. Shah was also previously co-founder and Chairman of Ezose Sciences, a high throughput glycomics company launched out of Hokkaido University pioneering novel techniques for glycoprotein biomarker discovery.

Dr. Shah began his career at McKinsey & Company, advising pharmaceutical and biotech clients on a wide range of R&D, commercial and corporate strategy matters.  He earned his Ph.D. degree in Molecular Biophysics and Biochemistry from Yale University and holds BA degrees in Mathematics and Biochemistry from the Integrated Science Program at Northwestern University.

   

Michael Singer, M.D., Ph.D.
 

Chief Scientific Officer
Cartesian Therapeutics

Email: michael.singer@thirstybrook.com

Industries and Specialities

Biotech, Ophthalmology, Immunology

Michael Singer is a serial entrepreneur, investor, and ophthalmologist. He has co-founded several life sciences companies, including HealthHonors (sold to Healthways in 2009) and Topokine (sold to Allergan in 2016). Most recently he co-founded Cartesian Therapeutics, a clinical-stage company developing a new generation of Chimeric Antigen Receptor T-cell (CAR-T) products. Mike is also a registered patent agent. He is named as inventor on over 50 issued patents and has written over 25 peer-reviewed scientific papers. Mike completed his B.S. in Biology, Ph.D. in Neuroscience, and M.D. at Yale, followed by internship and residency at Harvard.

David Shapiro, M.B.A.
 

Founding Managing Partner
Blue Ivy Ventures

Email: david@blueivyventures.com

Industries and Specialities

Consulting, Financial Services

David has over 25 years experience as an investor, with expertise across early and late stage venture capital, growth investing, and secondary deals. He currently is the Founding Managing Partner of Blue Ivy Ventures, a private, for-profit venture fund for Yale alums to invest in alumni related businesses. Previously, he was Senior VP Corporate Development and Business Development for DataXu, a marketer-aligned data and analytics company. Prior to that, he was a Director with the global venture and private equity firm 3i, and Co-founder and COO of Exygy, a startup focused on GPS and wireless technology. He also worked in the PE group at GE Asset Management, specializing in late stage venture and growth capital opportunities. David received his BA in History from Yale in 1991 and MBA from the Tuck School of Business at Dartmouth.

Matthew Stannard, M.S.
 

Investor
Angel Investor Forum

Email: mattstannard@yahoo.com

Industries and Specialities

Drug Development, Medical Devices, Financial Services

Matthew is an investor as part of the Angel Investor Forum primarily focused on priced-equity opportunities in life science and health technology-driven startups that serve an unmet medical need and are likely to have a significant positive impact on public health and well-being. He is an entrepreneurial drug and medical device development professional with more than twenty years of multinational experience spanning the many facets of discovery, development and patient access; most recently led business and corporate development efforts for an Amsterdam-based digital health technology startup. 

Hyuk-Jeen Suh, Ph.D., M.B.A.
 

Head of Samsung Ventures East Coast
Samsung Venutres

Email: hyukjeen@gmail.com

Industries and Specialities

Financial Services, IT, High Technology & Processing

Hyuk-Jeen Suh founded and was the Head of the East Coast office for Samsung Ventures, which is the corporate venture arm of Samsung. He bringing over 20 years of industry experience in consumer electronics, biotech, and semiconductor. Before joining Samsung Ventures, Hyuk-Jeen worked at J.P. Morgan investment banking. He led global business development efforts at a semiconductor startup, MEMSIC, contributing to a successful IPO in 2007. Prior to joining MEMSIC, Hyuk-Jeen was a senior research engineer at Sequenom, a biotech startup. He began his career at Intel Corporation as a process engineer. He advises startup companies and speaks at universities including Yale, Harvard, and MIT. A selection of his investments include Adhawk, Callidus (acquired by Amicus Therapeutics), Carbon Design Systems (acquired by ARM), Cloudant (acquired by IBM), Fixmo (acquired by Good Technology), Ionic Materials, Maluuba (acquired by Microsoft), Magisto (acquired by Vimeo), Noom, Rounds (acquired by Kik), and WellDoc. Hyuk-Jeen earned his Ph.D. in electrical engineering from University of Illinois at Urbana-Champaign, MBA from Yale School of Management, B.S. in mechanical engineering, B.A in economics and M.E in electrical engineering, all from Cornell University.

Michael Theran
 

Chief Executive Officer and Founder
Bonde Innovations

Email: mtheran@corismacv.com

Industries and Specialities

Medical Devices, Cardiovascular

Michael Theran is founder and CEO of Bonde Innovations where he is developing a wireless, implantable circulatory assist device designed to disrupt the $1B LVAD heart failure medical device market. The technology is based on research from the Bonde Artificial Heart Laboratory at Yale University. He also worked as the VP of Research and Development at EpiEP Inc. After starting his career in consumer products as a product designer, product manager then engineering executive, Mr. Theran decided to focus on start-up companies in the life sciences including medical devices. Creating much needed and highly innovative new medical devices from university research has been Mr. Theran’s focus for the last 10 years. 

Mark Van Allen, M.B.A.
 

Global Managing Director
Morgan Pacific Company, LLC

Email: rmarkv@aol.com

Industries and Specialities

Drug Development, Financial Services, Medical Devices

Mark Van Allen is currently a consultant to startup companies in the US and China. Prior to this work, Mr. Van Allen was the President of the UConn Ventures, Inc. from January 2003 to June 2015. He has also held financial and operating positions in early stage investor-owned partnerships and companies. From 1995 to 2003, Mr. Van Allen was the Managing Director of Morgan Pacific Company, Inc., a firm involved in technology transfer opportunities and investment and market analysis in Asia for U.S. based technology companies. Morgan Pacific also developed distribution networks for U.S. technology firms selling products in China. Prior to Morgan Pacific, he worked for Donaldson, Lufkin & Jenrette and Rotan Mosle, Inc., two full-service investment banking houses in New York. He was part of the initial team charged with the development of Science Park (a Yale-initiated business incubator) in New Haven and also developed and served as President of the Bridgeport Innovation Center (a for-profit business incubator) for eight years. He has served as Chairman and President of the Connecticut Venture Group. He received a B.A. Degree, Human Biology, and an MBA Degree, Finance— both from Stanford University, Stanford, California.

Julie Vance
 

Communications Coach
Executive Voice

Email: julie.vance@yale.edu

Industries and Specialities

Consulting

Julie is the senior communication coach at Executive Voice. She helps entrepreneurs to articulate their vision and technical concepts to diverse constituencies, boosting their communicative strategies and enhancing the public delivery of their pitch content. Julie has coached individuals and teams in almost every division of Yale and supported corporate clients such as Deloitte, McKinsey, and Pfizer. Trained in psychology and linguistics (B.A., University of Pennsylvania), she shares fresh insights into pitch presentations, with her clients winning international competitions.  In support of the Blavatnik Fund for Innovation at Yale, Julie offers faculty pitch review and coaching sessions during the pre-proposal process, and intensive faculty finalist coaching in advance of the Yale Innovation Summit.

J. Gene Wang, M.D., Ph.D.
 

Chief Executive Officer
Immetas Therapeutics

Email: gene@immetas.com

Industries and Specialities

Drug Development, Therapeutics, Immunology, Oncology

Dr. J. Gene Wang is the CEO of Immetas Therapeutics, a biotech company he co-founded with David Sinclair at Harvard focusing on inflammation pathways in aging. He is a physician scientist with nearly two-decades experience in advancing scientific innovations across multiple therapeutic areas, including immunology/inflammation (Abbott, GSK & Novartis) and oncology (Merck). He created development strategies and led cross-functional teams in the successful development of Humira®, Varubi®, Zolinza® and Gardasil®. He also led efforts to identify novel targets and brought multiple first-in-class compounds to clinical-stage and proof-of-concept studies. Dr. Wang received M.D. from Peking University and Ph.D. in Immunobiology from Yale University, and he completed medical residency training at Yale New Haven Hospital.

Paul White
 

Chief Transformation Officer/Chief Financial Officer
Second Renaissance Ventures, LLC

Email: paulcwhite@gmail.com

Industries and Specialities

IT, Diagnostics, Consulting, Financial Services

Paul White is a transformative leader who thrives on driving sustainable revenue and bottom-line growth through innovation and collaboration, and embracing change, accountability and responsibility along the way. He has broad leadership experience as a CEO, CFO and COO in a variety of industries (Media, High Tech, Med Tech) and environments (Public, Private, Startup, For1une 1 K, 828, 82C) with a proven track record of initiating and driving recurring value creation and “making it actually happen” in terms of generating real revenues and profits where others have failed. Paul is a driven but balanced Executive with a progressive career in senior leadership, with strengths in finance, operations, digital business transformation and reinvention, sales and strategy in the media, healthcare and financial services industries. He is known for his ability to develop and execute on challenging initiatives and to attract, develop and lead the organizational talent required to effectively complete them. This translates to capturing literally 1 00s of millions of dollars in recurring revenues and bottom-line profits. Additionally, Paul brings an entrepreneurial perspective to the organization, working with the entire team to develop innovative ideas, processes and partnerships. 

Peter Young, M.S., M.B.A.
 

Chief Executive Officer, President, and Managing Partner
Young & Partners

Email: pyoung@youngandpartners.com

Industries and Specialities

Biotech, Drug Development, Financial Services

Mr. Young manages Young & Partners and is actively involved in client transactions and financings. Under his leadership, Young & Partners has established and maintained its position as a leader in the life science and chemical industries. The firm is in its 24th year. Prior to 1996, Mr. Young was Global Head of Chemicals Investment Banking at Lehman Brothers where he oversaw the worldwide efforts of Lehman in Chemicals. Previously he was head of the Chemical Groups at Salomon Brothers and Schroders. Early in his career while with Bain & Co., Mr. Young provided strategic advice to major chemical and life science companies. He also was a senior executive of J.H. Whitney & Co., one of the oldest venture capital firms, founded by the Whitney family, where he invested in pharmaceutical, biotech, and technology companies. As an investment banker, Mr. Young has been a financial advisor to a wide variety of leading life science and chemical companies globally with regard to strategic financial advice, mergers, acquisitions, restructurings and capital raising. Mr. Young received an M.B.A. from the Harvard Business School (Baker Scholar with Highest Distinction), an M.S. in Accounting from New York University and a B.A. in Economics from Yale University.

Andrew Zehner, M.A., J.D.
 

Senior Director of Legal Affairs
University of Pennsylvania Gene Therapy Program

Email: andrewzehner@gmail.com

Industries and Specialities

Consulting, Drug Development, IT

Andrew Zehner currently serves as the Senior Director of Legal Affairs at the University of Pennsylvania Gene Therapy Program. Andrew has twenty-five years of experience providing strategic and business counsel to a wide variety of industries, including life sciences, health care, telecommunications, and information technology. Prior to Penn, he worked as Associate Vice President for Technology Commercialization at the University of Connecticut and counsel in the Office of the General Counsel. Earlier in his career, Andrew worked as Senior Corporate Counsel for Pfizer Inc., supporting all aspects of pharmaceutical R&D in the U.S. and United Kingdom. 

Find our Investor Advisors here.

Monday, November 25, 2019